Trial Profile
Phase II Trial of STI571 [imatinib mesylate] (NSC 716051) in Patients With Recurrent Meningioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 23 Nov 2008 Completion date November 2008 as reported by ClinicalTrials.gov.
- 23 Nov 2008 Completion date November 2008 as reported by ClinicalTrials.gov.
- 23 Nov 2006 Status change